GSK opens S$130m facilities in Jurong
New plant and expanded building will step up pharmaceutical firm's output of active ingredients in its HIV medication
Add BT as a preferred source
Singapore
PHARMACEUTICAL giant GlaxoSmithKline (GSK) unveiled a new, fully automated continuous manufacturing facility and an expanded production building at its Jurong site on Friday, worth a total of S$130 million.
The site upgrades will accelerate GSK's global supply chain and, in particular, its production of active pharmaceutical ingredients (APIs) such as Dolutegravir and Lamivudine, key assets in GSK's HIV medication.
TRENDING NOW
Shanda co-founder sells Tanglin Hill bungalow for S$76 million
Jumbo Seafood to close flagship East Coast Seafood Centre outlet on Sep 30
Nearly half of Apac’s wealthy expect market crash or correction, plan to rotate to cash: study
Trek 2000 shares jump 41.5% after Osim founder Ron Sim drops claims, sells 7.3% stake to Azure Capital
